

How to Prescribe Jakafi[™]

Jakafi is available through a limited network of Specialty Pharmacies. The IncyteCARES program was created to facilitate patient access to Jakafi and is available toll-free for all healthcare providers, patients and their caregivers at 1-855-4-Jakafi (855-452-5234).

Please follow these steps to successfully prescribe Jakafi for your patients:

Step 1: Complete the Program Enrollment Form

Both you and the patient complete and sign, then FAX the one-page Jakafi Enrollment Form to IncyteCARES at 1-855-525-7207. This form will serve as the patient's initial prescription for Jakafi. Be sure to have the patient check the enrollment boxes for both the Access and Reimbursement Services and the Education and Support Services, if they would like to participate in these services.

Step 2: Insurance Verification

The IncyteCARES program will confirm your patient's insurance coverage. Once verified, your patient's prescription will be sent to a Specialty Pharmacy. Through IncyteCARES a comprehensive co-payment assistance and free-drug program is available for eligible patients.*

Step 3: Medication sent from a Specialty Pharmacy

Your patient will be assigned to a Specialty Pharmacy that provides the lowest patient out-of-pocket cost for Jakafi. The Specialty Pharmacy will collect co-payments, provide refill reminders, and ship Jakafi directly to your patient.

^{*}Co-pay assistance program not available in all states or for patients who are receiving prescription reimbursement under any federal, state, or government-funded programs. Enrollment necessary.



IncyteCARES Program Connecting to Access, Reimbursement, Education and Support

P.O. Box 221798 • Charlotte, NC 28222-1798 • Phone: 1-855-4-Jakafi (855-452-5234) • Fax: 1-855-525-7207

IncyteCARES offers two services: 1.) Access and Reimbursement services assist patients starting on JakafiTM (ruxolitinib) 2.) Education and Support services encourage patients to stay on Jakafi

1 Physician Information	A Patient Information
	Patient Name:
Physician Name:	Shipping Address:
Site/Facility Name:	City: State: Zip:
Street Address:	Date of Birth: SSN:
City: State: Zip:	Phone Number: Best Time to Call:
Office Contact:Telephone:	Alternate Phone Number:
Fax:Best Time to Call:	Primary Language:
Office Contact E-mail:	E-mail Address:
State License #: Payer Specific ID#:	Alternate Contact and Phone Number:
Tax ID #:NPI #:	B Patient Insurance Information
Patient Clinical Information (Please complete A - D)	Primary Rx Insurer:
(Telephone:
A) Patient Diagnosis / ICD-9 Code:	Policy ID Number: Group Number:
☐ 238.76 Myelofibrosis with myeloid metaplasia ☐ 289.83 Myelofibrosis ☐ Other diagnosis:	Subscriber Name/Date of Birth:
	Secondary Rx Insurer:
B) Does the patient have intermediate or high-risk myelofibrosis?	Telephone:
☐ Yes ☐ No	Policy ID Number: Group Number:
C) Previous or Current Myelofibrosis Therapies:	Subscriber Name/Date of Birth:
Does this patient have or has had any previous MF therapies?	Please include a photocopy of the patient's insurance card(s), if possible.
☐ Yes: ☐ No	
D) Contact for IncyteCARES to call to discuss this patient's therapy?	C Patient Financial Information*
	Current annual household income: \$ Number of household members dependent on income stated above
Name at () – Title (eg, MD, RN, BSN, MSN, PA, NP)	(include applicant):
ride (eg, mb, mb, mbn, mbn, mbn, mbn, mbn, mbn,	*If you would like to be considered for co-pay or product support please provide income information for potential eligibility determination. If approved for support,
3 Prescription	documentation (latest tax return or W2 or one month of pay stubs) will be required within 90 days.
Upon confirmation of insurance coverage (or the patient's approval for assistance through	
the Program), medication should be shipped via a specialty pharmacy provider to the patient's home address (listed above, right) unless otherwise indicated by practitioner:	D Patient Authorization for the IncyteCARES Program
	Access and Reimbursement Services
Patient Name: Date: Date: Product Name: Jakafi [™] (ruxolitinib)	I understand my physician has authorized IncyteCARES to request a benefits verification to determine if my prescription for Jakafi is covered under my health insurance. I have requested that IncyteCARES determine my lightly the control of the con
Dosage: ☐ 5 mg ☐ 10 mg ☐ 15 mg ☐ 20 mg ☐ 25 mg	eligibility for co-pay assistance or free drug. If IncyteCARES needs to verify my financiál or insurance information, I authorize my healthcare providers or my insurance company to disclose information about me.
Sig: Twice a day Quantity:	I understand that any co-pay assistance or free drug provided to me through IncyteCARES is contingent upon meeting certain eligibility criteria and that Incyte has the right at any time, and without notice, to modify or
Refill(s): DEA #:	discontinue IncyteCARES or any assistance provided to me.
Ship to: Patient's home Doctor's office	I understand that I can cancel this authorization at any time by writing to IncyteCARES at the address above. If I cancel this authorization, then my healthcare providers and my insurance company will not provide any further information about me, and IncyteCARES will no longer provide me with assistance.
Is there a preferred Specialty Pharmacy?	Information about the, and incyteCARES will no longer provide the with assistance. I understand that once IncyteCARES receives information about me, federal privacy laws may no longer apply.
is there a preferred specialty mannacy.	I also understand that IncyteCARES will only use or disclose information about me to operate the Program and provide services to me or to assist me in finding alternative sources of funding or coverage for my treatment.
4 Physician Declaration	I understand that I do not have to sign this authorization to obtain treatment or seek payment for treatment on my own; however, in order to be eligible for the services provided by IncyteCARES I must sign the authorization.
verify that the patient and physician information contained in this enrollment form is complete and accurate to the	Education and Support Services I authorize Incyte and affiliated companies to use and release information about me to its agents working on its
best of my knowledge and that I have prescribed Jakafi based on my professional judgment of medical necessity.	to the distribution of the purposes of providing education and ongoing support services to me for Isadeins working in the to use and give out my information, send me materials related to Jakafi or other information in which I might be
I represent and warrant that I have my patient's authorization on file to disclose their health information and to transfer such authorization to Incyte and its agents to use and disclose such information as necessary to provide reimbursement services and to forward this prescription to a dispensing pharmacy on behalf of my patient.	to use and give out my information, send me materials related to Jakan or other information in which i might be interested, and to contact me by e-mail, mail, or phone on occasion regarding these services or for feedback about Jakafi, or as required or permitted by law.
I appoint IncyteCARES solely to convey on my behalf to the pharmacy chosen by or for the above-named patient, the	I acknowledge that I am a resident of the United States and verify that the information provided in this enrollment form is current, complete, and accurate.
prescription described herein. I authorize IncyteCARES to perform a preliminary assessment of insurance verification for the above-named patient,	This authorization expires in ten (10) years.
and I further authorize and request that the Program provide to me any and all information necessary for completing a Letter of Medical Necessity as may be required as a result of such insurance verification assessment.	I WISH TO BE ENROLLED AS FOLLOWS BY CHECKING THE APPROPRIATE BOX(ES)
	ACCESS AND REIMBURSEMENT SERVICES
Physician Signature:	By signing below I authorize IncyteCARES to contact me and notify me regarding my benefits
Date: /	Patient Signature: Date:/
Please fax to 855-525-7207	Legal Guardian or Representative Signature:
lakafi is a trademark of Insute Corporation	Legal Quardian of Representative Signature

© 2012, Incyte Corporation. All rights reserved.

RUX-1111

01/12

Relationship to Patient:



IncyteCARES Program Enrollment Instructions For Providers

The left-hand side of the form contains physician information needed for enrollment and physician must sign.

1 Physician Information	
-	Physician Information
Physician Name: <u>Lisa Smith, MD</u> Site/Facility Name: <u>Community Practice Providers, Inc</u>	Include practice contact information, office
Charact Address 2720 Diver Dood Cuits FOO	staff contact and any navor-specific provider ID
City: Springfield State: IL Zip: 62701	Step 1 stan contact and any payer-specific provider 1b number relevant for the patient's insurance to
Office Contact: Christy Jones Telephone: (555) 111-2222	facilitate quick and effective contact with the
Fax: (555) 111-3333 Best Time to Call: Before 2 PM	payer and your office. Please write legibly or type
Office Contact E-mail: cjones@cpp.com	information, if possible.
State License #: 12345 Payer Specific ID#: 09876	
Tax ID #: 45678	Patient Clinical Information
Patient Clinical Information (Please complete A - D) A) Patient Diagnosis / ICD-9 Code: □ 238.76 Myelofibrosis with myeloid metaplasia □ Other diagnosis: □ Other diagnosis: □ No C) Previous or Current Myelofibrosis Therapies: □ Does this patient have or has had any previous MF therapies? □ Yes: □ No D) Contact for IncyteCARES to call to discuss this patient's therapy?	This section is required and could delay the verification process if not completed. This information will help with enrollment into copay assistance and/or prior authorization assistance. Please complete A - D: A) Patient's diagnosis B) Indicate if the patient has intermediate or high-risk myelofibrosis according to the IWG criteria C) Previous or current myelofibrosis therapy (this may be substituted with last chart note) D) If a program oncology nurse needs to discuss patient clinical information with the office, please
Name Lisa Smith at (555) 111 – 2222 Title (eg, MD) RN, BSN, MSN, PA, NP) Prescription	include whom they should speak with and their contact information. Prescription
Upon confirmation of insurance coverage (or the patient's approval for assistance through the Program), medication should be shipped via a specialty pharmacy provider to the patient's home address (listed above, right) unless otherwise indicated by practitioner: Patient Name: Date: Date: Date: Product Name: Jakafi TM (ruxolitinib)	Include patient name, dosage, quantity, refills, DEA # and date to complete the prescription. A separate prescription is not needed.
Dosage: ☐ 5 mg ☐ 10 mg ☐ 15 mg ☑ 20 mg ☐ 25 mg Sig:	Please check the box to indicate if Jakafi should be shipped to the patient's home or the doctor's office. Also, if there is a preferred in-network specialty pharmacy, please list this here.
4 Physician Declaration	1
Verify that the patient and physician information contained in this enrollment form is complete and accurate to the	
best of my knowledge and that I have prescribed Jakafi based on my professional judgment of medical necessity. I represent and warrant that I have my patient's authorization on file to disclose their health information and to transfer such authorization to Incyte and its agents to use and disclose such information as necessary to provide	Physician Declaration
reimbursement services and to forward this prescription to a dispensing pharmacy on behalf of my patient. I appoint IncyteCARES solely to convey on my behalf to the pharmacy chosen by or for the above-named patient, the prescription described herein.	Step 4 A physician signature is required in order for IncyteCARES to perform a benefit verification.

Completed forms can be faxed to 1-855-525-7207 or mailed to IncyteCARES program P.O. Box 221798 Charlotte, NC, 28222-1798

I authorize IncyteCARES to perform a preliminary assessment of insurance verification for the above-named patient, and I further authorize and request that the Program provide to me any and all information necessary for completing a Letter of Medical Necessity as may be required as a result of such insurance verification assessment.

Physician Signature: Lisa Smith



IncyteCARES Program Enrollment Instructions For Patients/Caregivers

The right-hand side of the form contains patient information needed for enrollment and the patient must sign.

Patient Contact Information

Include patient and alternate contact name and relationship, with alternate phone numbers and best time to call, so the program can call to discuss benefits and the specialty pharmacy can call to schedule delivery.

Patient Information Patient Name: Richard Simons Shipping Address: 1234 Green Tree Road City: Small Town **Zip:** 62700 **Date of Birth:** _08/24/67 SSN: 100-00-0001 **Phone Number:** (555) 100-5000 Best Time to Call: Early Evening Alternate Phone Number: (555) 200-6000 Primary Language: English E-mail Address: Richard@email.com Alternate Contact and Phone Number: Betty Simons (wife), (555) 100-5001

Patient Insurance Information

Group Number: 77777

Group Number: 55555

Patient Rx Insurance Information

Include patient's Rx insurance information: Rx plan name, ID, group # and phone # to facilitate contact with the patient's Rx insurance company to verify benefits. Please include a photocopy of the Rx insurance card(s), if possible.

Policy ID Number: 65432 Subscriber Name/Date of Birth: Richard Simons, 08/24/67 Step 2

Step 1

Financial Information

Include current annual household income and the number of dependents (including patient) if the patient would like to be considered for copay or free drug assistance.

Patients will be temporarily approved if they meet the eligibility requirements but must provide income documentation (latest tax return, W2, or one month of pay stubs) within 90 days to remain eligible for assistance.

Step 3

Patient Financial Information*

Please include a photocopy of the patient's insurance card(s), if possible.

Current annual household income: \$ 78,000

Secondary Rx Insurer: Secondary Rx Insurance Co

Subscriber Name/Date of Birth: Betty Simons, 04/22/71

Primary Rx Insurer: Rx Insurance Co.

Telephone: (630) 444-0000

Telephone: (630) 555-1111

Policy ID Number: 99999

Number of household members dependent on income stated above

(include applicant): 3

*If you would like to be considered for co-pay or product support please provide income information for potential eligibility determination. If approved for support, documentation (latest tax return or W2 or one month of pay stubs) will be required within 90 days.

Patient Authorization for the Program

Include patient or quardian signature and date. Signature is required in order for IncyteCARES to contact the patient with the results of the benefits verification.

Step 4

Check the applicable boxes to be considered for co-pay and free drug assistance and to enroll in the patient education and support services.

Patient Authorization for the IncyteCARES Program Access and Reimbursement Services

I understand my physician has authorized IncyteCARES to request a benefits verification to determine if my prescription for Jakafi is covered under my health insurance. I have requested that IncyteCARES determine my eligibility for co-pay assistance or free drug. If IncyteCARES needs to verify my financial or insurance information, I authorize my healthcare providers or my insurance company to disclose information about me.

I understand that any co-pay assistance or free drug provided to me through IncyteCARES is contingent upon meeting certain eligibility criteria and that Incyte has the right at any time, and without notice, to modify or discontinue IncyteCARES or any assistance provided to me.

I understand that I can cancel this authorization at any time by writing to IncyteCARES at the address above. If I cancel this authorization, then my healthcare providers and my insurance company will not provide any further information about me, and IncyteCARES will no longer provide me with assistance.

I understand that once IncyteCARES receives information about me, federal privacy laws may no longer apply. I also understand that IncyteCARES will only use or disclose information about me to operate the Program and provide services to me or to assist me in finding alternative sources of funding or coverage for my treatment.

I understand that I do not have to sign this authorization to obtain treatment or seek payment for treatment on my own; however, in order to be eligible for the services provided by IncyteCARES I must sign the authorization.

Education and Support Services

I authorize Incyte and affiliated companies to use and release information about me to its agents working on its behalf for the purposes of providing education and ongoing support services to me for Jakafi. I authorize incyte to use and give out my information, send me materials related to Jakafi or other information in which I might be interested, and to contact me by e-mail, mail, or phone on occasion regarding these services or for feedback about Jakafi, or as required or permitted by law.

I acknowledge that I am a resident of the United States and verify that the information provided in this enrollment form is current, complete, and accurate

This authorization expires in ten (10) years.

1	I WISH TO BE ENROLLED AS FOLLOWS BY CHECKING THE APPROPRIATE BOX(ES)		
	🛮 ACCESS AND REIMBURSEMENT SERVICES 🔻 EDUCATION AND SUPPOR	T SERVICES	
	By signing below I authorize IncyteCARES to contact me and notify me regarding my benefits		
	Patient Signature: Richard Simons	Date: <u>01 / 01 / 2012</u>	
	Legal Guardian or Representative Signature: N/A	_ Date:/	
	Relationship to Patient: N/A		

Completed forms can be faxed to 1-855-525-7207 or mailed to IncyteCARES program P.O. Box 221798 Charlotte, NC, 28222-1798